Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.42 |
| ▸ | PRKACA | P17612 | 2/20 | 0.42 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.42 |
| ▸ | GSK3A | P49840 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4A | O75164 | 2/20 | 0.38 |
| ▸ | KDM4B | O94953 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460818 | 0.81 | DAPK3 (0.54) | BRD4DAPK3PRKD3PIM1PDGFRA | |
| SCHEMBL17164025 | 0.79 | BRD4 (0.42) | BRD4DAPK3PRKD3PIM1PDGFRA | |
| SCHEMBL4903819 | 0.77 | HPGD (0.47) | BRD4DAPK3PRKD3PIM1PDGFRA | |
| SCHEMBL31132800 | 0.76 | BRD4 (0.40) | BRD4DAPK3PRKD3PIM1PDGFRA | |
| SCHEMBL20187962 | 0.76 | HTT (0.43) | BRD4DAPK3PRKD3PIM1PDGFRA | |
| SCHEMBL1149887 | 0.74 | PDE5A (0.52) | BRD4DAPK3PRKD3PIM1PDGFRA | |
| SCHEMBL31133071 | 0.72 | HPGD (0.40) | BRD4DAPK3PRKD3PIM1PDGFRA | |
| SCHEMBL20196460 | 0.70 | BRD4 (0.33) | BRD4 | |
| SCHEMBL19917188 | 0.68 | KDM5B (0.40) | BRD4DAPK3PRKD3PIM1PDGFRA | |
| SCHEMBL21273002 | 0.67 | PIM1 (0.43) | BRD4DAPK3PRKD3PIM1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110225911-B | Oxadiazolone transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3526239-B1 | HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES | OLIPASS CORP (KR) | 2021-11-03 | — | — | EP | disclosed |
| EP-3544979-B1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| EP-3544979-B1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-08-04 | — | — | EP | disclosed |
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3544979-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-10-02 | — | — | EP | disclosed |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
| WO-2018096159-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913742-B2 | Oxadiazolones as transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | BRD4 3292/4885DAPK3 757/4885PRKD3 2897/4885 |
| US-20190284189-A1 | OXADIAZOLONES AS TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | BRD4 3292/4885DAPK3 757/4885PRKD3 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.